Status:
COMPLETED
Role of Inflammatory Markers in Sepsis
Lead Sponsor:
National Cancer Institute, Egypt
Conditions:
Diagnostic
Eligibility:
All Genders
18-65 years
Brief Summary
A diagnostic and prognostic study, in which the expression of CD64 in activated neutrophils and CD64 and IL17A regulatory T cells in patients with sepsis will be evaluated as a probable marker for sep...
Eligibility Criteria
Inclusion
- Cancer patients admitted to the surgical ICU following cancer related surgeries and diagnosed with sepsis
Exclusion
- Refusal of patient or patient guardian to participate.
- Intraoperative massive blood loss and massive blood transfusion
- Patients with impaired preoperative kidney or liver function tests
Key Trial Info
Start Date :
November 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 25 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06111963
Start Date
November 1 2023
End Date
January 25 2025
Last Update
July 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Walaa Y Elsabeeny
Cairo, Egypt, 11796